Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients - Full Text View

Purpose

The study will be a multi-center, parallel, group, placebo control, double-blind, randomized controlled trial of lamictal as add-on maintenance treatment in pediatric outpatients (aged 10 to 17 years) diagnosed with Bipolar I disorder. The study consists of 4 phases: Screen (approximately 2 weeks), Open label phase (up to 18 weeks), Randomized phase (up to 36 weeks) and Taper and follow-up phase (up to 4 weeks).

Condition	Intervention	Phase
Bipolar Disorder	Drug: lamictal	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age

Resource links provided by NLM:

MedlinePlus related topics: Bipolar Disorder

Drug Information available for: Lamotrigine

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

The primary efficacy endpoint is the time from randomization to the occurence of a bipolar event. [ Time Frame: 52 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Time from randomization to withdrawal from the study for any cause. Time from randomization to intervention for a mood episode. Time from randomization to intervention for depression, mania/hypomania, or a mixed episode. [ Time Frame: 52 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	340
Study Start Date:	July 2008
Estimated Study Completion Date:	September 2013
Estimated Primary Completion Date:	September 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: placebo Placebo Controlled	Drug: lamictal Flexible Dosing Other Name: lamictal
Experimental: lamictal Flexible Dosing	Drug: lamictal Flexible Dosing Other Name: lamictal

Eligibility

Ages Eligible for Study:	10 Years to 17 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Subject is male or female between the ages of 10 and 17 years, inclusive.
Subject has a diagnosis of bipolar I disorder and is currently experiencing a manic/hypomanic, depressed, or mixed mood episode
Subject is currently receiving a stable treatment regimen.
Subject is living with his/her custodial parent(s) or legal guardian(s) and has contact with them on a daily basis.

Exclusion Criteria

Subject has been diagnosed with a primary Axis I disorder (with the exception of bipolar I disorder, ADHD, anxiety disorders, oppositional defiant disorder, or conduct disorder) or any Axis II disorder.
Subject currently has signs or symptoms of psychosis or a history of psychosis within the previous four weeks.
Subject has been diagnosed with epilepsy, autism, Asperger's syndrome, or Tourette's syndrome.
Subject has experienced a serious rash, such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis, or a rash otherwise requiring hospitalization.
Subject has experienced a rash related to prior LAMICTAL use, or for whom LAMICTAL treatment was discontinued for clinically significant safety reasons.
Subject has received any antidepressant medication, or atomoxetine, during the four weeks prior to the Screen Visit.
Subject has initiated psychotherapy within 2 months prior to the Screen Visit, or plans to initiate psychotherapy during the trial.
Subject in the 10-12 year old age group has a Body Mass Index (BMI) less than or equal 15 or greater than or equal to 30; a subject in the 13-17 year old age group has a BMI less than or equal to 17 or greater than or equal to 34.
Subject tests positive for illicit drug use at the Screen Visit, has a history of alcohol or substance abuse or dependence (other than nicotine dependence) within the past three months, or has a positive blood alcohol level at the Screen Visit.
Subject, in the investigator's judgment, poses a current homicidal or serious suicidal risk, has made a suicide attempt within the twelve months preceding the Screen Visit, has ever been homicidal.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00723450

Locations

United States, California
GSK Investigational Site
San Diego, California, United States, 92108
GSK Investigational Site
Stanford, California, United States, 94305
United States, Georgia
GSK Investigational Site
Smyrna, Georgia, United States, 30080
United States, Kansas
GSK Investigational Site
Overland Park, Kansas, United States, 66211
United States, New Mexico
GSK Investigational Site
Albuquerque, New Mexico, United States, 87109
United States, Washington
GSK Investigational Site
Kirkland, Washington, United States, 98033

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials

GlaxoSmithKline

More Information

No publications provided

Responsible Party:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00723450 History of Changes
Other Study ID Numbers:	SCA102833
Study First Received:	July 24, 2008
Last Updated:	March 21, 2013
Health Authority:	United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:

Bipolar I pediatric lamictal adolescent

Additional relevant MeSH terms:

Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Lamotrigine
Calcium Channel Blockers
Membrane Transport Modulators

Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Anticonvulsants
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 16, 2013